Unum Therapeutics Added to NASDAQ Biotechnology Index
20 déc. 2018 07h00 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies,...
Unum Therapeutics Announces US Patent Protection for ACTR Technology
06 déc. 2018 07h00 HE
|
Unum Therapeutics Inc.
US Patent and Trademark Office Issues US Patent 10,144,770 Covering Antibody-Coupled T-cell Receptors (ACTR)Broad Claims Provide Composition of Matter Protection for Cell Therapies and Their Methods...
Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-20-03 at the 2018 ASH Annual Meeting
02 déc. 2018 21h00 HE
|
Unum Therapeutics Inc.
- Complete Responses Observed in Three of Six Patients at Dose Level 1 and One of Three Patients at Dose Level 2 - - No SAEs of Cytokine Release Syndrome or Neurological Events Observed in Dose...
Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-17-01 at the 2018 ASH Annual Meeting
01 déc. 2018 21h25 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Dec. 01, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), today announced preliminary results from the ongoing Phase 1 ATTCK-17-01 study, testing ACTR087 in...
CORRECTION: Unum Therapeutics to Host Investor Event on its Efforts to Realize the Promise of T Cell Therapies in Solid Tumors
12 nov. 2018 18h13 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Unum Therapeutics Inc. (NASDAQ: UMRX), please note the investors event date has been...
Unum Therapeutics to Host Investor Event on its Efforts to Realize the Promise of T Cell Therapies in Solid Tumors
12 nov. 2018 16h01 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies,...
Unum Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
12 nov. 2018 16h01 HE
|
Unum Therapeutics Inc.
- ACTR707 in Combination with Rituximab Selected as Lead Product Candidate for Further Development in r/r NHL – - New Solid Tumors Technology Platform Revealed at SITC – - More Details on Solid...
Unum Therapeutics to Present Preclinical Data on Applications of ACTR Proprietary Technology Platform in Solid Tumors at the San Antonio Breast Cancer Symposium
09 nov. 2018 14h31 HE
|
Unum Therapeutics Inc.
Initiating Phase 1 ATTCK-34-01 Trial in HER2+ Advanced Cancers by Year-End CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage...
Unum Therapeutics to Present Preclinical Data on a New, Emerging Platform Technology for Solid Tumors at the SITC Annual Meeting
06 nov. 2018 08h01 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), today announced that the Company will present preclinical data on a new proprietary technology platform...
Unum Therapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on November 12, 2018 at 4:30 P.M. ET
05 nov. 2018 07h00 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on...